Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease

Life Sciences

Volumn 92, Issue 4-5, 2013, Pages 311-316

  Lin, Ling ^a   Meng, Tao ^a   Liu, Tingting ^a   Zheng, Zhihong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Dopamine; Keywords; Melatonin; Microdialysis; Parkinson's disease; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; MELATONIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MEDIAL FOREBRAIN BUNDLE; MICRODIALYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; ROTATION; SUBSTANTIA NIGRA PARS COMPACTA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DOPAMINE; HOMOVANILLIC ACID; MALE; MELATONIN; MICRODIALYSIS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84873729161     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.01.007     Document Type: Article

References (25)

1. P.A. Bartell, M. Miranda-Anaya, W. McIvor, and M. Menaker Interactions between dopamine and melatonin organize circadian rhythmicity in the retina of the green iguana J Biol Rhythms 22 2007 515 523
2. A. Borah, and K.P. Mohanakumar Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents J Pineal Res 47 2009 293 300
3. R. Bordet, D. Devos, S. Brique, Y. Touitou, J.D. Guieu, and C. Libersa Study of circadian melatonin secretion patterns at different stages of Parkinson's disease Clin Neuropharmacol 26 2003 65 72
4. P.M. Bungay, P. Newton-Vinson, W. Isele, P.A. Garris, and J.B. Justice Microdialysis of dopamine interpreted with quantitative model incorporating probe implantation trauma J Neurochem 86 2003 932 946
5. C. Capitelli, A. Sereniki, M.M. Lima, A.B. Reksidler, S. Tufik, and M.A. Vital Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats Eur J Pharmacol 594 2008 101 108
6. D.P. Cardinali, and P. Pévet Basic aspects of melatonin action Sleep Med Rev 2 1998 175 190
7. F. Dabbeni-Sala, S. Di Santo, D. Franceschini, S.D. Skaper, and P. Giusti Melatonin protects against 6-OHDA-nduced neurotoxicity in rats: a role for mitochondrial complex I activity FASEB J 15 2001 164 170
8. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrosrtiatal pathway Exp Neurol 175 2002 303 317
9. J. Ma, V.E. Shaw, and J. Mitrofanis Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord 15 2009 307 314
10. J.C. Mayo, R.M. Sainz, I. Antolin, and C. Rodriguez Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage Brain Res 818 1999 221 227
11. R.Y. Moore Neural control of the pineal gland Behav Brain Res 73 1996 125 130
12. W.W. Morgan, and J.F. Nelson Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway Brain Res 921 2001 115 121
13. D.R. Notter, and P. Chemineau Nocturnal melatonin and prolactin plasma concentrations in sheep selected for fertility in autumn lambing J Anim Sci 79 2001 2895 2901
14. S. Paus, T. Schmitz-Hübsch, U. Wüllner, A. Vogel, T. Klockgether, and M. Abele Bright light therapy in Parkinson's disease: a pilot study Mov Disord 22 2007 1495 1498
15. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 2006 Academic Press San Diego
16. J. Sastre Toraño, P.v. Rijn-Bikker, P. Merkus, and H.J. Guchelaar Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high performance liquid chromatography and fluorescence detection Biomed Chromatogr 14 2000 306 310
17. E. Schernhammer, H. Chen, and B. Ritz Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer Causes Control 17 2006 577 582
18. S. Singh, R. Ahmed, R.K. Sagar, and B. Krishana Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat Indian J Med Res 124 2006 419 426
19. N.K. Singhal, G. Srivastava, S. Agrawal, S.K. Jain, and M.P. Singh Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol Neurobiol 45 2012 186 199
20. V. Tapias, J.R. Cannon, and J.T. Greenamyre Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model J Neurosci Res 88 2010 420 427
21. G.L. Willis Intraocular microinjections repair experimental Parkinson's disease Brain Res 1217 2008 119 131
22. G.L. Willis Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process Rev Neurosci 19 2008 245 316
23. G.L. Willis, and S.M. Armstrong A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease Physiol Behav 66 1999 785 795
24. G.L. Willis, and A.D. Robertson Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor Pharmacol Biochem Behav 79 2004 413 429
25. G.L. Willis, A.M. Kelly, and G.A. Kennedy Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model Behav Brain Res 193 2008 37 47